<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460265</url>
  </required_header>
  <id_info>
    <org_study_id>20050251</org_study_id>
    <nct_id>NCT00460265</nct_id>
  </id_info>
  <brief_title>Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer</brief_title>
  <acronym>SPECTRUM</acronym>
  <official_title>A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the treatment effect of Panitumumab in combination
      with chemotherapy versus chemotherapy alone as first line therapy for metastatic and/or
      recurrent squamous cell carcinoma of the head and neck.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Upto 56 months</time_frame>
    <description>Time from randomization to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Every 6 weeks until disease progression, up to 56 months</time_frame>
    <description>An objective tumor response of complete or partial response per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 that was confirmed no less than 28 days after the criteria for response were first met. Complete response = disappearance of all target lesions and partial response = ≥30% reduction in lesion size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Every 6 weeks until disease progression, up to 56 months</time_frame>
    <description>Time from the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) to disease progression using a modified version of the RECIST v1.0 (see protocol Appendix H).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Every 6 weeks until disease progression, up to 56 months</time_frame>
    <description>Time from randomization date to date of disease progression using a modified version of the RECIST 1.0 (see protocol Appendix H)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Every 6 weeks until disease progression, upto 56 months</time_frame>
    <description>Time from randomization date to the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) using a modified version of the RECIST v1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Every 6 weeks until disease progression or deaths, upto 56 months</time_frame>
    <description>Time from randomization date to date of disease progression using a modified version of the RECIST v1.0 or death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">658</enrollment>
  <condition>Recurrent and/or Metastatic Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 consists of Cisplatin and 5-FU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM 1 Consists of Panitumumab plus Cisplatin and 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARM 2</intervention_name>
    <description>Subjects will receive Cisplatin plus 5FU</description>
    <arm_group_label>ARM 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARM 1</intervention_name>
    <description>Subjects will receive Panitumumab plus cisplatin and 5FU</description>
    <arm_group_label>ARM 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman at least 18 years old.

          -  Histologically or cytologically confirmed metastatic and/or recurrent squamous cell
             carcinoma (or its variants) of the head and neck.

          -  Diagnosis of metastatic disease and/or recurrent disease following locoregional
             therapy and determined to be incurable by surgery or radiotherapy.

          -  Subjects who have received radiation as primary therapy are eligible if locoregional
             recurrence is in the field of radiation and has occurred ≥6 months after the
             completion of radiation therapy. Subjects whose locoregional recurrence is solely
             outside the field of radiation are eligible if the recurrence has occurred ≥ 3 months
             after the completion of radiation therapy.

          -  Measurable and non-measurable disease.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

        Exclusion Criteria:

          -  History or known presence of Central Nervous System (CNS) metastases.

          -  History of another primary cancer, except: curatively treated in situ cervical cancer,
             or curatively resected non-melanoma skin cancer, or other primary solid tumor
             curatively treated with no known active disease present and no treatment administered
             for ≥ 2 years before randomization.

          -  Nasopharyngeal carcinoma.

          -  Prior systemic treatment for metastatic and/or recurrent SCCHN

          -  Prior cisplatin containing induction chemotherapy followed by cisplatin containing
             chemoradiotherapy

          -  Prior anti-EGFr (Epidermal growth factor receptor) antibody therapy or treatment with
             small molecule EGFr inhibitors

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) less than or equal to 1 year prior to randomization. History of
             interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of
             interstitial lung disease on baseline chest computerized tomography (CT) scan.

          -  Symptomatic peripheral neuropathy grade ≥ 2 based on the CTCAE v3.0

          -  Grade ≥ 3 hearing loss based on the Common Terminology Criteria for Adverse Events
             (CTCAE) v3.0 Auditory/Ear (Hearing [without monitoring program])
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Bach B, et al.SPECTRUM biomarkers HPV.Journal-004521;</citation>
  </reference>
  <reference>
    <citation>Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6.</citation>
    <PMID>23746666</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>May 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2011</results_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Epidermal Growth Factor</keyword>
  <keyword>Epidermal Growth Factor Receptor</keyword>
  <keyword>SCCHN</keyword>
  <keyword>Metastatic Head and Neck Cancer</keyword>
  <keyword>EGFr</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Recurrent Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 25 May 2007 to 10 March 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Panitumumab Plus Chemotherapy</title>
          <description>Consists of Panitumumab plus Cisplatin and 5-FU</description>
        </group>
        <group group_id="P2">
          <title>Chemotherapy Alone</title>
          <description>Consists of Cisplatin and 5-FU</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="328"/>
                <participants group_id="P2" count="330"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized While Alive</title>
              <participants_list>
                <participants group_id="P1" count="327">1 subject was randomized by error after death</participants>
                <participants group_id="P2" count="330"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="243">Completed study=death</participants>
                <participants group_id="P2" count="241">Completed study=death</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panitumumab Plus Chemotherapy</title>
          <description>Consists of Panitumumab plus Cisplatin and 5-FU</description>
        </group>
        <group group_id="B2">
          <title>Chemotherapy Alone</title>
          <description>Consists of Cisplatin and 5-FU</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="327"/>
            <count group_id="B2" value="330"/>
            <count group_id="B3" value="657"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="8.5"/>
                    <measurement group_id="B2" value="58.6" spread="7.8"/>
                    <measurement group_id="B3" value="58.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborigine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previously treated with chemotherapy and/or radiotherapy, Yes/No</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG perfomance score, 0/1/2</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="228"/>
                    <measurement group_id="B3" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary tumor site, oropharynx&amp;larynx/oral cavity&amp;hypopharynx</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Oropharynx and larynx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral cavity and hypopharynx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Time from randomization to death</description>
        <time_frame>Upto 56 months</time_frame>
        <population>Intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab Plus Chemotherapy</title>
            <description>Consists of Panitumumab plus Cisplatin and 5-FU</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Alone</title>
            <description>Consists of Cisplatin and 5-FU</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from randomization to death</description>
          <population>Intention to treat (ITT)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="9.8" upper_limit="12.2"/>
                    <measurement group_id="O2" value="9.0" lower_limit="8.1" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1403</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by IVRS randomization factors (ECOG(0:1),previously treated w/ CT/RT(yes:no),primary tumor site(oropharynx/larynx:oral cavity/hypopharynx))</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.873</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.729</ci_lower_limit>
            <ci_upper_limit>1.046</ci_upper_limit>
            <estimate_desc>Hazard ratio from Cox proportional hazards model stratified by IVRS randomization factors; hazard ratio presented as panitumumab plus chemotherapy:chemotherapy alone.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>An objective tumor response of complete or partial response per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 that was confirmed no less than 28 days after the criteria for response were first met. Complete response = disappearance of all target lesions and partial response = ≥30% reduction in lesion size.</description>
        <time_frame>Every 6 weeks until disease progression, up to 56 months</time_frame>
        <population>The subset of subjects in the ITT analysis set with at least one baseline uni-dimensionally measurable lesion using a modified version of the RECIST v1.0 (see protocol Appendix H)</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab Plus Chemotherapy</title>
            <description>Consists of Panitumumab plus Cisplatin and 5-FU</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Alone</title>
            <description>Consists of Cisplatin and 5-FU</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>An objective tumor response of complete or partial response per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 that was confirmed no less than 28 days after the criteria for response were first met. Complete response = disappearance of all target lesions and partial response = ≥30% reduction in lesion size.</description>
          <population>The subset of subjects in the ITT analysis set with at least one baseline uni-dimensionally measurable lesion using a modified version of the RECIST v1.0 (see protocol Appendix H)</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>10.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.13</ci_lower_limit>
            <ci_upper_limit>18.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Time from the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) to disease progression using a modified version of the RECIST v1.0 (see protocol Appendix H).</description>
        <time_frame>Every 6 weeks until disease progression, up to 56 months</time_frame>
        <population>Included only those subjects with a confirmed complete or partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab Plus Chemotherapy</title>
            <description>Consists of Panitumumab plus Cisplatin and 5-FU</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Alone</title>
            <description>Consists of Cisplatin and 5-FU</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Time from the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) to disease progression using a modified version of the RECIST v1.0 (see protocol Appendix H).</description>
          <population>Included only those subjects with a confirmed complete or partial response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="4.8" upper_limit="6.2"/>
                    <measurement group_id="O2" value="5.7" lower_limit="4.7" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time from randomization date to date of disease progression using a modified version of the RECIST 1.0 (see protocol Appendix H)</description>
        <time_frame>Every 6 weeks until disease progression, up to 56 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab Plus Chemotherapy</title>
            <description>Consists of Panitumumab plus Cisplatin and 5-FU</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Alone</title>
            <description>Consists of Cisplatin and 5-FU</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time from randomization date to date of disease progression using a modified version of the RECIST 1.0 (see protocol Appendix H)</description>
          <population>ITT</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="5.9" upper_limit="6.9"/>
                    <measurement group_id="O2" value="5.6" lower_limit="5.2" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time from randomization date to the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) using a modified version of the RECIST v1.0.</description>
        <time_frame>Every 6 weeks until disease progression, upto 56 months</time_frame>
        <population>Included only those subjects with a confirmed complete response or partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab Plus Chemotherapy</title>
            <description>Consists of Panitumumab plus Cisplatin and 5-FU</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Alone</title>
            <description>Consists of Cisplatin and 5-FU</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time from randomization date to the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) using a modified version of the RECIST v1.0.</description>
          <population>Included only those subjects with a confirmed complete response or partial response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.3" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.3" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Time from randomization date to date of disease progression using a modified version of the RECIST v1.0 or death.</description>
        <time_frame>Every 6 weeks until disease progression or deaths, upto 56 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab Plus Chemotherapy</title>
            <description>Consists of Panitumumab plus Cisplatin and 5-FU</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Alone</title>
            <description>Consists of Cisplatin and 5-FU</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Time from randomization date to date of disease progression using a modified version of the RECIST v1.0 or death.</description>
          <population>ITT</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.6" upper_limit="6.6"/>
                    <measurement group_id="O2" value="4.6" lower_limit="4.1" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.780</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.659</ci_lower_limit>
            <ci_upper_limit>0.922</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model stratified by IVRS randomization factors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The day of the first dose of study therapy through 33 days since the last dose date (up to 56 months)</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panitumumab Plus Chemotherapy</title>
        </group>
        <group group_id="E2">
          <title>Chemotherapy Alone</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Haematotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Ichthyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Aphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Necrotising colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Laryngotracheitis obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Myiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pleural infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Spinal shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Feeding disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Oropharyngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Radiculitis lumbosacral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Increased viscosity of bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Laryngeal dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Iliac artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="311" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="301" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

